Parnell Pharmaceuticals Holdings Ltd
PARNF
Other OTC0.08
USD
-0.08
- -
ISIN
AU0000XINEU9
Return %
Stock
S&P500
1Y
79,900.00
26.53
3Y
3,709.52
76.60
5Y
-55.56
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Brad R. McCarthy CPA
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Century Estate Alexandria NSW Australia 2015
- IPO Date
- Jun 18, 2014
- Website
- parnell.com
- Similar Companies
- Business
- Parnell Pharmaceuticals Holdings Ltd (PARNF) is a fully integrated veterinary pharmaceutical company that develops, manufactures, and commercializes animal health solutions for companion animals, production animals, and performance animals. The company offers a portfolio of core products including reproductive hormone therapies such as estroPLAN and GONAbreed for dairy and beef cattle breeding programs; osteoarthritis treatments like Zydax for dogs and horses and Glyde nutraceuticals for canine osteoarthritis; respiratory disease solutions such as RESPIRmycin for bovine respiratory disease; anesthesia and sedation products including PropofolVet Multidose (generic propofol injectable emulsion), Parnell Brand Dexmedetomidine Hydrochloride Injection, and CONTRASED (atipamezole hydrochloride); anti-inflammatory injectables like Tergive (carprofen); and digital platforms such as mySYNCH for herd fertility management and analytics. It operates through segments encompassing Companion Animal, Production Animal U.S., Production Animal Rest of World, and Manufacturing Operations, with manufacturing in FDA- and EMA-accredited sterile facilities. Parnell markets its products in 14 countries across North America, Latin America, Europe, Asia, the Middle East, Africa, Australia, and New Zealand, targeting veterinarians, livestock producers, and pet care professionals. Founded in 2009 and headquartered in Alexandria, New South Wales, Australia, the company maintains key operations including a U.S. presence in Overland Park, Kansas. In recent developments, Parnell launched PropofolVet Multidose in January 2025 as the first generic propofol injectable emulsion for canine anesthesia; introduced a Veterinary Certificate program in Anesthesia and Sedation on January 21, 2025; added two new sedation products to its pet care line in May 2024; welcomed Dr. Chelsie Estey as Vice President of U.S. Pet Care in March 2024; and launched RESPIRmycin in January 2023. The company faces a pending acquisition proposal by RCBC BidCo Pty Ltd announced on November 29, 2024, with an expected completion by March 19, 2025, subject to extension; earlier, DW Healthcare Partners invested in 2021 following a tender offer.
Head to Head Comparison: Parnell Pharmaceuticals (OTCMKTS:PARNF) and Assembly Biosciences (NASDAQ:ASMB)